Once monthly injectables to become future therapeutic options for obesity: Report
The report by GlobalData, a data and analytics company, showed that anti-obesity medications are the industry trend that will ...
pulmonologyadvisor11 天
FDA Approves First Generic Version of Victoza for Type 2 Diabetes
The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.
Yahoo Finance1 个月
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of ...
Second, Amneal has received approval from the FDA for exenatide, which is the Company’s first generic injectable glucagon-like peptide-1 (GLP-1) agonist and reflects its innovation capabilities ...
来自MSN1 个月
Goodbye Injections? What to Know About the Weight Loss Pills on the Horizon
Popular weight management drugs like Ozempic only come in injectable form ... companies are working to create a pill version of a glucagon-like peptide 1 (GLP-1) receptor agonist, which would ...
Outsourcing-pharma8 天
Verdiva Bio launches with $411m in funding to advance obesity drugs
Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...
pharmaphorum7 天
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
The company is still digging for efficacy signals among subpopulations in the CedLara trial, but has switched its attention to vurolenatide, an injectable glucagon-like peptide-2 (GLP-2 ...
Yahoo Finance1 个月
Amneal files again for FDA approval of first dihydroergotamine autoinjector
In the same release announcing its NDA resubmission, Amneal also reported it has received FDA approval for exenatide – a generic injectable glucagon-like peptide-1 receptor agonist (GLP-1RA).